SHANGHAI -- Dizal Pharmaceutical, a joint venture between China's state-owned SDIC Fund Management, AstraZeneca and Zytz Partners, has announced the closing of a $100 million financing round led by Lilly Asia Ventures.
New investors Sequoia Capital China, Trinity Innovation Fund and Wuxi NewForce Fund also participated in the round, according to a company statement on Wednesday.
